Mandibular bone loss: a hidden side effect of botulinum toxin type A injection in masticatory muscles. by Balanta-Melo, Julián & Buvinic, Sonja
Perspective
ISSN Online 0719-2479 - www.joralres.com © 201844
Conflict of interests:  Authors have no conflict 
of interests to declare.
Acknowledgements:  This work was supported 
by the FONDECYT Chile Grants Nº 
1151353 (SB), CONICYT Chile Scholarship 
Nº 21170015 (JB) and the Program Professor 
Scholarship Semillero Docente 2014 of the 
Universidad del Valle, Colombia (JB).  
Cite as: Balanta-Melo J & Buvinic S.  Man-di-
bular bone loss: a hidden side effect of botu-
linum toxin type A injection in masticatory 
muscles. J Oral Res 2018; 7(2):44-46. 
doi:10.17126/joralres.2018.014
Botulinum toxin type A (BoNTA) is the most potent serotype of a group of 
neurotoxins produced by obligate anaerobic bacteria Clostridium botulinum. 
This neurotoxin blocks the release of acetylcholine from the motor neuron, 
uncoupling the neuromuscular junction that results in a reversible paralysis 
of skeletal muscles that lasts for 4 – 6 months in humans.1 Commercially 
available forms of BoNTA (e.g. Botox®, Dysport®, Xeomin®) are increasingly 
used by dentists worldwide.1 In dentistry, conditions that affect masticatory 
muscles such as benign masseter hypertrophy and myofascial pain are treated 
with intramuscular injections of BoNTA,1,2 However, this neurotoxin is not 
approved for interventions in the masticatory apparatus, according to the US 
Food and Drug Administration (Allergan Full Prescribing Information for 
Botox®); as such, its clinical use is off-label.
The effects of BoNTA in skeletal muscles include paralysis, weakness, 
and atrophy,1 but much less studied are the side effects that could affect 
bone homeostasis. The musculoskeletal system maintains a fine regulation 
between muscles and bones, in which both tissues sustain a cross-talk 
through biomechanical (generation of force, tension) and biochemical signals 
(molecules released by the muscle that contribute to bone homeostasis and 
vice versa).3 So, what happens to the structure and function of the adjacent 
bone when muscle paralysis is induced by BoNTA injection?
The intramuscular (IM) intervention with BoNTA promotes bone loss 
in underlying structures. As demonstrated by Warner et al in adult female 
C57BL/6 mice, IM intervention in the quadriceps and calf muscles with 
Botox® (0.5U/19.2µl) significantly reduced the trabecular bone volume 
fraction by 43%, in the distal femoral epiphysis and by 54% in proximal 
tibial metaphysis after 21 days.4 In the same model, Aliprantis et al described 
that acute bone loss induced by this intervention occurs as a response to a 
significant increase of the receptor activator for nuclear factor Kappa Beta 
ligand (RANKL) in the proximal tibia metaphysis. 
RANKL is necessary to differentiate and increase the number of osteoclasts 
(bone resorption cells). Moreover, the treatment with human recombinant 
osteoprotegerin (the RANKL physiological antagonist), or conditional deletion 
of the osteoclastogenesis master regulator “nuclear factor of activated T-cells c1” 
(NFATc1), prevented the bone loss in this animal model.5 In addition, direct 
effects of BoNTA on bone cells were not detected, suggesting that bone loss 
may be produced by muscle load or signaling after this intervention.5 
Considering that the temporomandibular joint requires the activity of 
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masticatory muscles for its development and homeostasis, 
it is highly relevant to understand the effect of the BoNTA 
intervention in the masticatory apparatus. Kün-Darbois et al.,6 
reported trabecular bone loss in alveolar (-20%) and condylar 
(-35%) areas in adult rats 4 weeks after a unilateral injection 
of 1U of Botox® in both the masseter and temporalis muscles.
The same intervention in masseter muscles of growing mice 
(5 weeks-old) resulted in a significant decrease in condylar 
width of the treated side after 4 weeks. Moreover, decreased 
cell proliferation and increased cell death by apoptosis was 
observed in subchondral bone of the mandibular condyle.7 
Recently, our group assessed the effect of unilateral injection 
of Botox® in masseter muscle (0.2U/10µl) of adult BALB/c 
mice (8 weeks-old) at molecular and microstructural levels.8 
Our results demonstrated a significant increase in the 
mRNA expression of RANKL in the mandibular condyle of 
the treated side 2 days after intervention. Also, there was a 
significant increase in the mRNA expression of both atrophy 
(atrogin-1/MAFbx and MURF-1) and muscle regeneration 
markers (myogenin) in the treated masseter muscles after 7 
days. These findings, together with the significant reduction 
in the masseter mass and muscle fibers diameter at the 
BoNTA-injected side observed after 14 days, support the 
hypothesis that molecular events precede the onset of BoNTA-
induced masseter muscle atrophy. In addition, the bone 
histomorphometry performed on the mandibular condyles at 
14 days post-intervention showed a significant reduction of 
the trabecular bone (-30%) and trabecular thickness (−55%). 
Taken as a whole, these results demonstrate that masseter 
muscle atrophy induced by BoNTA single injections leads to 
significant microanatomical changes in the masseter muscle 
and the mandibular condyle of the same side after 14 days, 
preceded by molecular changes as early as 2 days in bone and 
7 days in muscle.8 
In humans, the bone effects derived from IM injection of 
BoNTA in masticatory muscles have been much less studied 
and are more difficult to address. In a pilot qualitative 
study, cone-beam computed tomography (CBCT) images 
of mandibular condyles from 7 adult female patients with 
temporomandibular joint dysfunction (TMJD), receiving two 
or more BoNTA IM injections for facial pain, were compared 
with those from 9 demographically matched control patients.9 
Two independent oral and maxillofacial radiologists, blinded 
to BoNTA exposure conditions, rated bone density patterns 
in the trabecular region of mandibular heads. 
Both radiologists noted a reduction in bone density in all 
the patients exposed to BoNTA, and in none of the 9 control 
subjects.9 In a recent Letter to the Editor, Aziz et al.,10 
introduced the clinical case of a patient (female, 55 years-
old) with a 13-year history of TMJD and a Meige Syndrome 
diagnosis. Comparing magnetic resonance imaging and 
computed tomography data within a time span of 15 months, 
in which the patient admitted she had privately had Botox® 
injections every three months (140U) into her left masseter, 
a severe mandibular condyle resorption of the treated side 
was observed. 
Authors are cautious to point out that is difficult to tell if 
Botox® was the cause of bone resorption, because this is an 
isolated cause and iatrogenic injury cannot be excluded. However, 
they highlight the idea that the condylar degeneration may be 
associated with BoNTA injections. These reports, reinforced by 
results from experimental studies in animal models, makes it 
highly recommended for both clinicians and patients to consider 
the putative bone loss evoked by BoNTA-induced masseter muscle 
atrophy as a relevant factor prior to a treatment.10 Therefore, the 
presented evidence suggests the importance of considering the 
need to develop follow-up protocols to permanently monitor the 
associated bone structure by proper imaging techniques after 
BoNTA intervention in the masseter muscle. This is especially 
relevant in patients who require multiple successive applications 
of toxin to maintain the desired effect. Finally, there is not 
enough evidence to know if BoNTA intervention in the masseter 
muscle (or other masticatory muscles) predisposes, initiates or 
perpetuates the TMJD.
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